

January 5, 2021

Press Release

Company Name: J-Pharma Co., Ltd.
Contact: Yoshinori Bamba, Director,
Corporate Planning Dept.
Tel: 045-506-1155
info@j-pharma.com

J-Pharma Co., Ltd. to Present at The 39th Annual J.P. Morgan Healthcare Conference

Yokohama, Japan, January 5, 2021 – J-Pharma Co., Ltd. (“J-Pharma”), a clinical stage biopharmaceutical company, has announced that J.P. Morgan have invited them to present at the 39th Annual J.P. Morgan Healthcare Conference in January 2021. The J.P. Morgan Healthcare Conference attracts over 500 companies and 12,000 investors and is going virtual for 2021. A webcast will be made available online following the live event.

Max Yoshitake, President and CEO of J-Pharma will present on January 12, 2021, at 7:30 AM EST and give a brief introduction to the company’s clinical programs focusing on Solute Carrier (SLC) transporters, particularly L-type amino acids transporter (LAT1/SLC7A5). He will introduce a pivotal registration clinical study of its original LAT1 inhibitor, JPH203, to treat advanced biliary tract cancers (BTC) patients who are refractory or intolerant to standard chemotherapy. He will also touch on global business development strategies and timelines.

Additionally, he will introduce the development programs for OKY-034 to treat refractory advanced pancreatic cancer and LAT1 inhibitors to treat autoimmune diseases.

About J-Pharma

Name	J-Pharma Co., Ltd.
Location	75-1 Onocho, Tsurumi-ku, Yokohama, Kanagawa
Representative Director	Max Yoshitake, President & CEO
Business Activities	Pharmaceutical Research & Development
Capital	50 million JPY (as of May 31, 2020)
Establishment	26 th December 2005

Company Homepage

<http://www.j-pharma.com>

About JPH203 and OKY-034

JPH203 is J-Pharma's original small molecule competitively inhibiting amino acid binding pocket of LAT1 which expresses on the cell membrane when a cell needs huge amounts of energy due to rapid proliferation and/or activation. JPH203 is the first LAT1-targeted compound undergoing clinical studies and will become the first-in-class medicine when approved by competent authorities. J-Pharma confirmed its tolerability and preliminary efficacy in advanced solid cancer patients through a Phase 1 study. They also discovered a biomarker capable of distinguishing a patient sub-population that will have fewer adverse events and be more susceptible to JPH203. Using this biomarker as a companion diagnostic, JPH203 is now undergoing a Phase 2 clinical study to treat advanced biliary tract cancer patients who are refractory or intolerant to standard chemotherapy.

OKY-034 is a novel small molecule allosterically binding the LAT1 and holding the amino acid up-taking movements of LAT1. J-Pharma executed a worldwide, exclusive license (with sub-license) agreement with Osaka University and KNC Laboratories Co., Ltd., both of which possess the composition patent for OKY-034. At Osaka University, a physician-sponsored Phase 1/2a clinical study of OKY-034 is underway to treat advanced, unresectable pancreatic cancer patients who are refractory or intolerant to standard chemotherapy.